
Free Daily Podcast Summary
by IASLC
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.Lung Cancer considered is funded in part by Current sponsors: • AbbVie • AstraZeneca• Gilead• J&J• Summit
The most recent episodes — sign up to get AI-powered summaries of each one.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about breakthrough advances in thoracic oncology presented at the conference with Dr. Jorge Alatorre Alexander and Dr. Miguel Gonzalez Velez. Guests: Jorge Alatorre Alexander, MD Head of the Medical Oncology Service National Institute of Respiratory Diseases (INER) Miguel Gonzalez Velez, MD Medical Oncologist John Theurer Cancer Center at Hackensack University Medical Center
The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about breakthrough advances in thoracic oncology presented at the conference with Dr. Lilian Faroni and Dr. Vladmir Cordeiro de Lima. Guests: Lilian Faroni, MD, PhD Radiation Oncologist Oncologia D’Or Rio de Janeiro, Brazil Vladmir Cordeiro de Lima, MD, PhD Thoracic and Breast Oncologist A.C. Camargo Cancer Center, São Paulo, Brazil
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer. Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice. Guests: Dr. Julia Rotow Clinical Director and Research Director, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Dr. Roy Herbst Director, Dartmouth Cancer Center Professor, Geisel School of Medicine at Dartmouth Dr. Daniel Shao-Weng Tan Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore Professor, Duke-NUS Medical School Senior Clinician-Scientist, Genome Institute of Singapore
The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about breakthrough advances in thoracic oncology presented at the conference with Dr. Zhengfei Zhu, Dr. Yun Fan, and Dr. Dongsheng Yue. Guests: Dr. Yun Fan, MD, PhD Chief Expert of the Multidisciplinary Lung Cancer Team, Zhejiang Cancer Hospital; Senior Consultant (Grade II Chief Physician); Doctoral Supervisor Dr. Dongsheng Yue, MD, PhD Tianjin Medical University Cancer Institute and Hospital Dr. Zhengfei Zhu, MD, PhD Department of Radiation Oncology Fudan University Shanghai Cancer Center
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday. A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Attending Physician, Thoracic Oncology Service Giannis Mountzios, MD, MSc, PhD Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center Athens, Greece,
From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC. Both guests share what patients and community oncologists should take from the data. Guests: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Chad G. Rusthoven, MD Adjunct Associate Professor University of Colorado University of North Carolina at Chapel Hill
Get ready for WCLC 2026 in Seoul with Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez. From preparing for the flight and beating jet lag to navigating COEX, networking, exploring Seoul’s food scene, and making the most of the meeting, they share practical tips to help attendees arrive prepared and enjoy the full WCLC experience.
In this episode, Dr. Narjust Florez is joined by Dr. Yasir Elamin and Dr. Liliana Faroni to explore the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care. Guests: Yasir Elamin, MD Associate Professor of Thoracic Medical University of Texas MD Anderson Cancer Center Liliana Faroni, MD, PhD Radiation Oncologist, Oncologia D’Or Rio de Janeiro
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.Lung Cancer considered is funded in part by Current sponsors: • AbbVie • AstraZeneca• Gilead• J&J• Summit
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Lung Cancer Considered in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Lung Cancer Considered as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by IASLC.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
Lung Cancer Considered publishes 2x weekly. Our AI generates a summary within hours of each new episode.
Lung Cancer Considered covers topics including Science. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.